Their formulation successfully enhanced the therapeutic effect of the combined form of the drugs based on the active targeting of them to HER2-positive cells and the synergic effect of the co-administration of trastuzumab monoclonal antibodies with Paclitaxel and Gemcitabine on HER2-positive cancer cells, also protecting the normal cells from the side effects of the drugs [142]. This evidence concerns the gene ERBB2 and cancer.